Painchek Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from PainChek
- Strongly Supported A$7.5m Placement to Drive Int. Growth
- Final US FDA De Novo Clearance Submission Completed
- PainChek Reports Strong Quarterly Sales Growth
- PainChek has productive final FDA De Novo clearance meeting
- PainChek partners with Eldermark to expand US market reach
Later from PainChek
- Compelling Clinical and Economic Results in Scottish Pilot
- Trading Halt
- PainChek FDA Cleared to Commence Sales in US$100M US Market
- PainChek Secures First US Customer Following FDA Clearance
- Response to ASX Aware Letter
Follow PainChek into a list and get an email when it puts out news.
Follow PainChek